BQ123/788

PreclinicalSmall molecule

UUniversity of Edinburgh

BQ123/788 is one of 43 small molecule programs targeting Vasculitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VasculitisActive, not recruiting

VasculitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

58 competitors in Vasculitis

#DrugCompanyPhaseTrials

Plaquenil

Alnylam Pharmaceuticals

Approved

1 2

Imuran

LLegacy Health System

Approved

8 3

Campath

GGenzyme, a Sanofi Company

Approved

1 4

Glucocorticoids

Novartis

Approved

3 5

Colcrys

Alnylam Pharmaceuticals

Phase 3

2 6

Medrol

Pfizer

Phase 3

2 7

Trexall

Alnylam Pharmaceuticals

Phase 3

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 3

5 9

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

2 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vasculitis1 trial

Endothelin Antagonism in ANCA Vasculitis

Completed·UUniversity of Edinburgh·N/A·NCT02062346·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BQ123/788. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BQ123/788 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BQ123/788. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Edinburgh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Edinburgh

BQ123/788

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vasculitis1 trial

References

Drug Info

Quick Facts

Related News